This approach has been used for several other parasitic vaccines, including those for malaria [6] and hookworm [12], and is often incorporated into a conventional compliance or single data point testing approach [10] such as shown in Fig. 1, where potencies of the first two clinical lots of Sm-TSP-2/Al were estimated using a relative potency (RP) metric. The gene discussed is THBS2; the disease is malaria.